Sfoglia per Rivista
[A case of 'non-secretory' myeloma turned into 'secretory' pathogenetic hypothesis (author's transl)]
1977-01-01 GIOVANELLI E ;NERETTO G ;CODA R
A new non canonical role of IkB-alpha in chronic myleoid leukemia pathogenesis
2013-01-01 S Crivellaro; C Panuzzo; G Carrà; F Crasto; R lorenzatti; F Daraio; F Carnuccio; G Saglio; A Morotti
A new oncogenic role of BCR-ABL/OOF in chronic myeloid leukemia pathogenesis
2013-01-01 C Panuzzo; S Crivellaro; C Casnici; E Cibrario; F Crasto; R Lorenzatti; F Daraio; K Crotta; G Carrà; A Morotti; G saglio; G Volpe
A PHASE 3 STUDY TO DETERMINE THE EFFICACY AND SAFETY OFLENALIDOMIDE COMBINED WITH MELPHALAN AND PREDNISONE INPATIENTS = 65 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA(NDMM)
2010-01-01 A Palumbo; M Dimopoulos; M Delforge; R Hajek; M Kropff; MT Petrucci; Z Yu; L Herbein; J Mei; C Jacques; J Catalano
A PHASE III STUDY OF ENOXAPARIN VS ASPIRIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED OF MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE-BASED REGIMENS.
2011-01-01 F. CAVALLO; T. CARAVITA; F. DI RAIMONDO; G. CICCONE; B. LUPO; M. MARCATTI; A. BARALDI; N. PESCOSTA; A.P. FALCONE ;R. RIA; L. BALDINI; L. MASINI; T. GUGLIELMELLI; G. GAIDANO; G. BENEVOLO; C. CANGIALOSI ; M. GALLI ; L. CATALANO; A. LAROCCA; A. NAGLER; M. BOCCADORO; A. PALUMBO
A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS
2014-01-01 Dario Ferrero; Elena Crisà; Filippo Marmont; Ernesta Audisio; Chiara Frairia; Valentina Giai; Tiziana Gatti; Moreno Festuccia; Benedetto Bruno; Ludovica Riera; Roberto Passera; Mario Boccadoro
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
2011-01-01 Zangari M; Yaccoby S; Pappas L; Cavallo F; Kumar NS; Ranganathan S; Suva LJ; Gruenwald JM; Kern S; Zhan F; Esseltine DL; Tricot G.
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL
2007-01-01 Sorasio R; Patriarca F; Giaccone L; Mattei D; Allione B; Carnevale-Schianca F; Rambaldi A; Casini M; Montefusco V; Parma M; Bavaro P; Onida F; Busca A; Castagna L; Iori AP; Rotta M; Fiore F; Benedetti E; Mordini N; Massaia M; Palumbo A; Aglietta M; Lewis A; Foà R; Di Bartolomeo P; Pogliani E; Lambertenghi-Deliliers G; Falda M; Petrini M; Corradini P; Fanin R; Ricardi U; Ciccone G; Baldi I; Bruno B; Boccadoro M
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia
2006-01-01 GALANELLO R; KATTAMIS A; PIGA A; FISCHER R; LEONI G; LADIS V; VOI V; LUND U; TRICTA F
A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIB-MELPHALANPREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA:EFFECT OF AGE AND CO-MORBIDITIES
2010-01-01 A Palumbo; S Bringhen; D Rossi; M Cavalli; R Ria; M Offidani; C Nozzoli; L Baldini; L De Rosa; G De Sabbata; AM Liberati; C Crippa; F Ciambelli; V Callea; M Spriano; F Ferrara; F Elice; M Galli; J Peccatori; L Catalano; M Rizzo; R Marasca; F Pisani; M Cavo; M Petrucci; P Musto; P Omedè; A Larocca; G Gaidano; M Boccadoro
A retrospective real-life analysis of chronic myeloid leukemia patients in suboptimal response to imatinib: three centres experience.
2012-01-01 Ferrero D; Crisà E; Rege-Cambrin G; Fava C; Cerrano M; Pirillo F; Nicolosi M; Boccadoro M; Saglio G; Vitolo U; Pregno P.
A SALVAGE TREATMENT CONTAINING NOVEL AGENTS CONSOLIDATED BY ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED-INTENSITY CONDITIONING IMPROVES OUTCOME OF MULTIPLE MYELOMA PATIENTS FAILING AUTOLOGOUS TRANSPLANTATION
2011-01-01 F. PATRIARCA H. EINSELE; F. SPINA; B. BRUNO; M. ISOLA; C.NOZZOLI; A. NOZZA; A. SPEROTTO; F. MORABITO; G. STUHLER; M. FESTUCCIA; A. BOSI; R. FANIN; P. CORRADINI
A very sensitive and rapid method for BCR-ABL T315Imutation detection by peptide nucleic acid directed PCR clamping
2009-01-01 E. Bracco; M. Spagna; R. Pedrola; V. Rosso; F. Arruga; M. Lo Iacono; S. Carturan; F. Messa; C. Panuzzo; P. Nicoli; E. Messa; A. Rotolo; A. Morotti; S. Mussino; A. Balbo; D. Cilloni; S.G. Saglio
Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia
2004-01-01 ROSSI D; CAPELLO D; GLOGHINI A; FRANCESCHETTI S; PAULLI M; BHATIA K; SAGLIO G; VITOLO U; PILERI SA; ESTELLER M; CARBONE A; GAIDANO G.
ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS
2010-01-01 F Gay; A Larocca; MT Petrucci; P Musto; AM Liberati; V Callea; R Ria; T Caravita; C Cangialosi; M Grasso; M Offidani; P Pregno; F Patriarca; M Galli; M Cavo; L Catalano; C Nozzoli; T Guglielmelli; R Zambello; F Pisani; V Montefusco; F Rossini; V De Stefano; B Lupo; F Di Raimondo; G Gaidano; M Boccadoro; A Palumbo
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
2013-01-01 Bringhen S;Mateos MV;Zweegman S;Larocca A;Falcone AP;Oriol A;Rossi D;Cavalli M;Wijermans P;Ria R;Offidani M;Lahuerta JJ;Liberati AM;Mina R;Callea V;Schaafsma M;Cerrato C;Marasca R;Franceschini L;Evangelista A;Teruel AI;van der Holt B;Montefusco V;Ciccone G;Boccadoro M;San Miguel J;Sonneveld P;Palumbo A
Aggressive subtypes of cutaneous T-cell lymphoma subsets: management and prognosis.
2003-01-01 BERNENGO M.G.; QUAGLINO P.
Alemtuzumab for the treatment of Sézary sindrome: clinical and immunological findings in 10 patients.
2006-01-01 Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Fierro MT.
ALTERNATIVE SPLICING VARIANT COULD BE RESPONSIBLE OF MORGANA UNDER-EXPRESSION IN ACML
2015-01-01 C. Panuzzo, G. Carrà, S. Crivellaro, R. Piazza, U. Familiari, S. Rocca, F. Fusella, G. Saglio, M. Brancaccio, A. Morotti
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
1999-01-01 BOCCADORO M ;TARELLA C ;PALUMBO A ;ARGENTINO C ;TRIOLO S ;DOMINIETTO A ;CALLEA V ;LAUTA VM ;MOLICA S ;MUSTO P ;MARMONT F ;GIANNI AM ;PILERI A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| [A case of 'non-secretory' myeloma turned into 'secretory' pathogenetic hypothesis (author's transl)] | 1977 | GIOVANELLI E ;NERETTO G ;CODA R | |
| A new non canonical role of IkB-alpha in chronic myleoid leukemia pathogenesis | 2013 | S Crivellaro; C Panuzzo; G Carrà; F Crasto; R lorenzatti; F Daraio; F Carnuccio; G Saglio; A Morotti | |
| A new oncogenic role of BCR-ABL/OOF in chronic myeloid leukemia pathogenesis | 2013 | C Panuzzo; S Crivellaro; C Casnici; E Cibrario; F Crasto; R Lorenzatti; F Daraio; K Crotta; G Carrà; A Morotti; G saglio; G Volpe | |
| A PHASE 3 STUDY TO DETERMINE THE EFFICACY AND SAFETY OFLENALIDOMIDE COMBINED WITH MELPHALAN AND PREDNISONE INPATIENTS = 65 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA(NDMM) | 2010 | A Palumbo; M Dimopoulos; M Delforge; R Hajek; M Kropff; MT Petrucci; Z Yu; L Herbein; J Mei; C Jacques; J Catalano | |
| A PHASE III STUDY OF ENOXAPARIN VS ASPIRIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED OF MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE-BASED REGIMENS. | 2011 | F. CAVALLO; T. CARAVITA; F. DI RAIMONDO; G. CICCONE; B. LUPO; M. MARCATTI; A. BARALDI; N. PESCOSTA; A.P. FALCONE ;R. RIA; L. BALDINI; L. MASINI; T. GUGLIELMELLI; G. GAIDANO; G. BENEVOLO; C. CANGIALOSI ; M. GALLI ; L. CATALANO; A. LAROCCA; A. NAGLER; M. BOCCADORO; A. PALUMBO | |
| A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS | 2014 | Dario Ferrero; Elena Crisà; Filippo Marmont; Ernesta Audisio; Chiara Frairia; Valentina Giai; Tiziana Gatti; Moreno Festuccia; Benedetto Bruno; Ludovica Riera; Roberto Passera; Mario Boccadoro | |
| A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients | 2011 | Zangari M; Yaccoby S; Pappas L; Cavallo F; Kumar NS; Ranganathan S; Suva LJ; Gruenwald JM; Kern S; Zhan F; Esseltine DL; Tricot G. | |
| A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL | 2007 | Sorasio R; Patriarca F; Giaccone L; Mattei D; Allione B; Carnevale-Schianca F; Rambaldi A; Casini M; Montefusco V; Parma M; Bavaro P; Onida F; Busca A; Castagna L; Iori AP; Rotta M; Fiore F; Benedetti E; Mordini N; Massaia M; Palumbo A; Aglietta M; Lewis A; Foà R; Di Bartolomeo P; Pogliani E; Lambertenghi-Deliliers G; Falda M; Petrini M; Corradini P; Fanin R; Ricardi U; Ciccone G; Baldi I; Bruno B; Boccadoro M | |
| A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia | 2006 | GALANELLO R; KATTAMIS A; PIGA A; FISCHER R; LEONI G; LADIS V; VOI V; LUND U; TRICTA F | |
| A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIB-MELPHALANPREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA:EFFECT OF AGE AND CO-MORBIDITIES | 2010 | A Palumbo; S Bringhen; D Rossi; M Cavalli; R Ria; M Offidani; C Nozzoli; L Baldini; L De Rosa; G De Sabbata; AM Liberati; C Crippa; F Ciambelli; V Callea; M Spriano; F Ferrara; F Elice; M Galli; J Peccatori; L Catalano; M Rizzo; R Marasca; F Pisani; M Cavo; M Petrucci; P Musto; P Omedè; A Larocca; G Gaidano; M Boccadoro | |
| A retrospective real-life analysis of chronic myeloid leukemia patients in suboptimal response to imatinib: three centres experience. | 2012 | Ferrero D; Crisà E; Rege-Cambrin G; Fava C; Cerrano M; Pirillo F; Nicolosi M; Boccadoro M; Saglio G; Vitolo U; Pregno P. | |
| A SALVAGE TREATMENT CONTAINING NOVEL AGENTS CONSOLIDATED BY ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED-INTENSITY CONDITIONING IMPROVES OUTCOME OF MULTIPLE MYELOMA PATIENTS FAILING AUTOLOGOUS TRANSPLANTATION | 2011 | F. PATRIARCA H. EINSELE; F. SPINA; B. BRUNO; M. ISOLA; C.NOZZOLI; A. NOZZA; A. SPEROTTO; F. MORABITO; G. STUHLER; M. FESTUCCIA; A. BOSI; R. FANIN; P. CORRADINI | |
| A very sensitive and rapid method for BCR-ABL T315Imutation detection by peptide nucleic acid directed PCR clamping | 2009 | E. Bracco; M. Spagna; R. Pedrola; V. Rosso; F. Arruga; M. Lo Iacono; S. Carturan; F. Messa; C. Panuzzo; P. Nicoli; E. Messa; A. Rotolo; A. Morotti; S. Mussino; A. Balbo; D. Cilloni; S.G. Saglio | |
| Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia | 2004 | ROSSI D; CAPELLO D; GLOGHINI A; FRANCESCHETTI S; PAULLI M; BHATIA K; SAGLIO G; VITOLO U; PILERI SA; ESTELLER M; CARBONE A; GAIDANO G. | |
| ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS | 2010 | F Gay; A Larocca; MT Petrucci; P Musto; AM Liberati; V Callea; R Ria; T Caravita; C Cangialosi; M Grasso; M Offidani; P Pregno; F Patriarca; M Galli; M Cavo; L Catalano; C Nozzoli; T Guglielmelli; R Zambello; F Pisani; V Montefusco; F Rossini; V De Stefano; B Lupo; F Di Raimondo; G Gaidano; M Boccadoro; A Palumbo | |
| Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials | 2013 | Bringhen S;Mateos MV;Zweegman S;Larocca A;Falcone AP;Oriol A;Rossi D;Cavalli M;Wijermans P;Ria R;Offidani M;Lahuerta JJ;Liberati AM;Mina R;Callea V;Schaafsma M;Cerrato C;Marasca R;Franceschini L;Evangelista A;Teruel AI;van der Holt B;Montefusco V;Ciccone G;Boccadoro M;San Miguel J;Sonneveld P;Palumbo A | |
| Aggressive subtypes of cutaneous T-cell lymphoma subsets: management and prognosis. | 2003 | BERNENGO M.G.; QUAGLINO P. | |
| Alemtuzumab for the treatment of Sézary sindrome: clinical and immunological findings in 10 patients. | 2006 | Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Fierro MT. | |
| ALTERNATIVE SPLICING VARIANT COULD BE RESPONSIBLE OF MORGANA UNDER-EXPRESSION IN ACML | 2015 | C. Panuzzo, G. Carrà, S. Crivellaro, R. Piazza, U. Familiari, S. Rocca, F. Fusella, G. Saglio, M. Brancaccio, A. Morotti | |
| An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. | 1999 | BOCCADORO M ;TARELLA C ;PALUMBO A ;ARGENTINO C ;TRIOLO S ;DOMINIETTO A ;CALLEA V ;LAUTA VM ;MOLICA S ;MUSTO P ;MARMONT F ;GIANNI AM ;PILERI A |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile